Q-omics provides the consensus-scored RPL5P25 profile across patient tissues and cancer cell-line models. RPL5P25 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, RPL5P25 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, RPL5P25 RNA expression shows 5,468 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight SKCM, BRCA, and STAD as cancer lineages where RPL5P25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL5P25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL5P25 survival associations across molecular data types. RPL5P25 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL5P25 RNA expression–survival associations across cancer types. High RPL5P25 expression shows unfavorable associations in ACC, LIHC, CHOL and UCEC, but favorable associations in SKCM and THCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .007). Together, the overview and detailed table identify SKCM as the clearest survival context for RPL5P25 RNA expression.
This table summarizes RPL5P25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL5P25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL5P25 shows lower tumor expression in BRCA, STAD and LUSC and higher tumor expression in THCA and LIHC. The BRCA box plot shows higher RPL5P25 RNA expression in normal versus tumor tissue (log2 FC = −0.059, t-test p = .004).
This table shows molecular features associated with RPL5P25 in patient tissues and cancer cell lines. In patient samples, RPL5P25 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
